Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Guidant Pixel

This article was originally published in The Gray Sheet

Executive Summary

Stent for treatment of small coronary vessels will debut in U.S. later this month in diameters of 2.0 mm, 2.25 mm and 2.5 mm. FDA approval via PMA supplement, announced July 9, allows use for abrupt or threatened closure due to unsuccessful interventional therapy in de novo and restenotic native coronary artery lesions. Device was launched in Europe earlier this year
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT015148

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel